Cowen Anticipates Dynavax’s Now-Approved Heplisav Will Lead the HBV Vaccine Market Sun, 12 Nov 2017 23:49:32 +0000 Dynavax Technologies (NASDAQ:DVAX) after five years of "torturous" waiting has at long last garnered FDA approval for Heplisav-B. Cowen analyst Phil Nadeau anticipates hundreds of millions of dollars to be made in the HBV vaccine market within 5 years.
At Long Last, Dynavax Wins FDA Approval For Heplisav Fri, 10 Nov 2017 13:44:17 +0000 Dynavax Technologies Corporation (NASDAQ: DVAX ), a clinical-stage immunotherapy company, confirmed on Thursday the U.S. Food and Drug Administration approved its two-dose vaccine The company failed to ...
Dynavax stock surges 18% on hepatitis B vaccine approval Fri, 10 Nov 2017 12:19:17 +0000 Dynavax Technologies Corporation shares surged 18% in premarket trade Friday after the company said its hepatitis B vaccine was approved by the Food and Drug Administration. The vaccine, Hepislav-B, is ...
Third time's the charm: East Bay drug maker wins FDA approval for hepatitis B vaccine Thu, 09 Nov 2017 22:44:45 +0000 An easier-to-take vaccine from an East Bay company, which could shift the fight against the surging, deadly hepatitis B virus, won regulatory approval Thursday. The company has spent hundreds of millions of dollars trying to develop the vaccine over more than a dozen years. The FDA rejected Heplisav B in February 2013 and delayed approval a year ago in order to study late-arriving data more closely.
Dynavax Technologies Corporation’s (DVAX) Hepatitis B Vaccine Wins FDA Approval Thu, 09 Nov 2017 22:12:53 +0000 Dynavax Technologies Corporation (NASDAQ:DVAX) has won U.S. Food and Drug Administration approval for its hepatitis B vaccine, HEPLISAV, ending a more than nine-year effort to bring the vaccine to the market. Dynavax shares reacted to the FDA approval, rising nearly 16% to $23.25 in after-hours trading. Hepatitis B is an extremely infectious and potentially deadly virus affecting a wide range of adults in the United States.
Should You Buy Arena Pharmaceuticals Inc (ARNA) At $27.23? Wed, 22 Nov 2017 13:09:10 +0000 Arena Pharmaceuticals Inc (NASDAQ:ARNA), a biotechnology company based in United States, saw a significant share price rise of over 20% in the past couple of months on the NasdaqGS. WithRead More...
Arena Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ARNA) : November 16, 2017 Thu, 16 Nov 2017 17:28:46 +0000 Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Arena Pharmaceuticals, Inc. a score of 59. Our analysis is based on comparing Arena Pharmaceuticals, Inc. with the following peers – VIVUS, Inc., Orexigen Therapeutics, Inc., Array BioPharma Inc., Athersys, Inc., Zafgen, Inc., GlaxoSmithKline plc Sponsored ADR and ReShape Lifesciences, Inc. (VVUS-US, OREX-US, ARRY-US, ATHX-US, ZFGN-US, GSK-US ... Read more
(Read more...)
Arena Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ARNA-US : November 15, 2017 Wed, 15 Nov 2017 12:50:19 +0000 Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Arena Pharmaceuticals, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish ... Read more
(Read more...)
Arena (ARNA) Completes Enrolment in Etrasimod Phase II Study Mon, 13 Nov 2017 14:44:02 +0000 Arena (ARNA) completed full enrollment with 157 patients in a phase II study evaluating etrasimod in ulcerative colitis (UC). Results from the study are expected in the first quarter of 2018.
Arena Pharmaceuticals Completes Full Enrollment in Etrasimod Phase 2 Clinical Study for Ulcerative Colitis Fri, 10 Nov 2017 16:31:00 +0000 SAN DIEGO, Nov. 10, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA), today announced that it has completed full enrollment in the etrasimod Phase 2 study in ulcerative colitis (UC). Etrasimod is an investigational-stage, oral, next-generation, sphingosine-1-phosphate (S1P) receptor modulator with improved pharmacology and pharmacokinetics intended for the treatment of autoimmune diseases.
Arena Pharmaceuticals (ARNA) Q3 Loss Widens Y/Y, Sales Beat Wed, 08 Nov 2017 14:53:02 +0000 Arena Pharmaceuticals (ARNA) reports another quarter of lackluster Belviq sales. However, the company is likely to advance ralinepag in phase III study based on positive data from the previous stage.
Arena Pharmaceuticals reports 3Q loss Tue, 07 Nov 2017 21:51:46 +0000 On a per-share basis, the San Diego-based company said it had a loss of 86 cents. Losses, adjusted for non-recurring costs, came to 65 cents per share. The results topped Wall Street expectations. The ...
Is It Time To Buy Lannett Company Inc (LCI) Based Off Its PE Ratio? Mon, 20 Nov 2017 21:55:05 +0000 Lannett Company Inc (NYSE:LCI) is trading with a trailing P/E of 21x, which is lower than the industry average of 23.5x. While LCI might seem like an attractive stock toRead More...
Scott+Scott, Attorneys at Law, LLP is Investigating Derivative Claims on Behalf of Shareholders of Lannett Company, Inc. (LCI) Thu, 09 Nov 2017 17:05:00 +0000 NEW YORK, Nov. 9, 2017 /PRNewswire/ -- Scott+Scott, Attorneys at Law, LLP ("Scott+Scott"), a national shareholder and consumer rights litigation firm, is investigating whether certain directors and officers of Lannett Company, Inc. ("Lannett" or the "Company") (LCI) breached their fiduciary duties to the Company and its shareholders. If you are a Lannett shareholder, you are encouraged to contact Scott+Scott for additional information. Lannett develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. On July 16, 2014, Lannett disclosed that it had received interrogatories and a subpoena from the State of Connecticut Office of the Attorney General concerning its investigation into the pricing of Digoxin, one of Lannett's generic drugs. By November 3, 2016, media outlets reported that Department of Justice ("DOJ") prosecutors were considering filing criminal charges against Lannett and several other generic pharmaceutical companies by the end of 2016 for unlawfully colluding to fix generic drug prices.
Lannett Comments On Amended Civil Complaint Wed, 01 Nov 2017 10:53:00 +0000 Lannett has reviewed the complaint and believes the price fixing allegations regarding the single product named in the complaint that Lannett sells are meritless. The company intends to vigorously defend the claims in the lawsuit.
Lannett And Celgene Enter Into Settlement And License Agreement Related To Thalomid® Mon, 30 Oct 2017 10:52:00 +0000 PHILADELPHIA, Oct. 30, 2017 /PRNewswire/ -- Lannett Company, Inc. (LCI) today announced that it has entered into a settlement and license agreement with Celgene Corporation that resolves patent infringement litigation in the U.S. related to Celgene's Thalomid®. The license agreement permits Lannett to manufacture and market in the U.S. its generic thalidomide product as of August 1, 2019 or earlier under certain circumstances. As mandated by the U.S. Food and Drug Administration (FDA), Thalomid® is subject to Risk Evaluation and Mitigation Strategies (REMS) program, which is designed and implemented during the commercialization of a pharmaceutical product to ensure an acceptable risk-to-benefit ratio for products that are known to exhibit specific risks.
UPDATE 2-Under pressure in diabetes, Novo Nordisk steps up focus on obesity drugs Tue, 21 Nov 2017 15:46:24 +0000 MÅLØV, Denmark, Nov 21 (Reuters) - Danish drugmaker Novo Nordisk is stepping up its efforts to treat obesity, seeking to tap into a potentially huge market as prices for its established diabetes drugs come under pressure, particularly in the United States. The world's largest maker of diabetes drugs said on Tuesday it would aim to develop medicines that treat obesity - a major cause of diabetes - at least as effectively as surgery.
Diabetes Community Awakens Important Conversation about Hidden Problem: Hypoglycemia Wed, 15 Nov 2017 16:00:00 +0000 TORONTO, Nov. 15, 2017 /CNW/ - Diabetes is one of the most challenging health problems in the 21st century. The number of people with the condition is increasing in every country worldwide, and Canada is no exception with 3.5 million people (or nearly one out of every three) living with diabetes.1 Nocturnal, or nighttime, hypoglycemia (low blood glucose levels) is a hidden problem within the diabetes community. Together, Novo Nordisk and Diabetes Canada are creating important conversations to shed light on the emotional, physical and financial impact of nighttime hypoglycemia.
Behind Sanofi’s 3Q17 Revenue Growth Tue, 14 Nov 2017 18:05:09 +0000 Sanofi (SNY) reported a growth of 4.7% in revenues at constant exchange rates to 9.05 billion euros, compared with 9.03 billion euros in 3Q16.
Novo Nordisk & 4 Other Pharma Stocks in Focus on World Diabetes Day Tue, 14 Nov 2017 14:29:02 +0000 Despite pricing pressure & competition, the diabetes market remains lucrative given the prevalence of the disease and demand for better treatments. Novo Nordisk (NVO) is a key player in this market.
*Winners defined as our Top Picks that increased 20% or more within a 6-month period.
Red Letters imply that that particular criteria did not meet minimum requirements, e.g., a low GSA Rank would show it in red.
___ Red Line On Graph Shows a Trailing Stop Loss Based on Support and Resistance Levels. See how it works.
___ Blue Line On Graph Shows the 10-Week Moving Average.
___ Magenta Line On Graph Shows the 40-Week Moving Average.
Disclaimer The stock selections in our stock investing and stock trading database are not stock recommendations, but simply represent applications of a stock investing process. All materials, including our Top Stock Picks, are provided for information purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security. Growth Stock Analytics, LLC is not responsible for gains/losses that may result in investing or trading in these securities. All information is believed to be obtained from reliable sources, but there is no guarantee that the information supplied is accurate, complete or timely. There is no guarantee or warranty with regard to the results obtained from its use. There is no guarantee of suitability or potential value of any particular investment or information source. You acknowledge that your requests for this information are unsolicited and shall neither constitute nor be considered investment advice. Past investing performance is not an indication of future performance results. Investing and trading in stocks is risky. Investors are encouraged to consult a registered stock broker or investment adviser before making any investing decisions. The interpretations and opinions expressed herein are solely those of Growth Stock Analytics, LLC, and not of any other individual or organization.